Clinical trial

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

NCT05568212

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-05-02

PhasePHASE2

Study timeline

Study start (actual)2022-05-02Date precision: day

Registry last updated2025-12-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small-cell Lung Cancer Patientsunresolved

Interventions

DurvalumabDRUG · verified · RxNorm: durvalumab

Olaparib tabletDRUG

Single-agent chemotherapyDRUG

Platinum doublet chemotherapyDRUG

Sponsors & collaborators

Fondazione Ricerca Traslazionalelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05568212 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.